Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma

Omid Hamid, MD
Published Online: Monday, Sep 11, 2017



Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase I/II results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

This was consistent with the initial results of the phase I trial, which demonstrated an overall response rate at around 55%, a disease control rate of about 70%, and an 18-month progression-free survival rate at more than 50%. Additionally, this was a very tolerable regimen that was not associated with significant toxicities.

This is important because prior combination therapies have shown similarly high response rates, but are linked with significant grade 3/4 toxicities—usually at 50%. Whereas, this combination showed grade 3/4 events at around 20% and a less than 10% grade 3/4 immune-related toxicities. This is a regimen that, if it shows benefit, then it is very translatable into the community, Hamid says. The phase III trial is currently ongoing, he concludes.

  <<< View more from the 2017 ESMO Congress


Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase I/II results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

This was consistent with the initial results of the phase I trial, which demonstrated an overall response rate at around 55%, a disease control rate of about 70%, and an 18-month progression-free survival rate at more than 50%. Additionally, this was a very tolerable regimen that was not associated with significant toxicities.

This is important because prior combination therapies have shown similarly high response rates, but are linked with significant grade 3/4 toxicities—usually at 50%. Whereas, this combination showed grade 3/4 events at around 20% and a less than 10% grade 3/4 immune-related toxicities. This is a regimen that, if it shows benefit, then it is very translatable into the community, Hamid says. The phase III trial is currently ongoing, he concludes.

  <<< View more from the 2017 ESMO Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
$emailPop$